1. Search Result
Search Result
Isoforms Recommended: GSK-3β
Results for "

GSK-3β

" in MedChemExpress (MCE) Product Catalog:

298

Inhibitors & Agonists

3

Fluorescent Dyes

5

Biochemical Assay Reagents

12

Peptides

46

Natural
Products

7

Recombinant Proteins

9

Isotope-Labeled Compounds

10

Antibodies

1

Click Chemistry

2

Oligonucleotides

3

GMP Molecules

Targets Recommended:
Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-14872
    Tideglusib
    5+ Cited Publications

    NP031112

    GSK-3 Neurological Disease
    Tideglusib (NP031112) is an irreversible GSK-3 inhibitor with IC50s of 5 nM and 60 nM for GSK-3β WT (1 h preincubation) and GSK-3β C199A (1 h preincubation), respectively.
    Tideglusib
  • HY-16294
    LY2090314
    15+ Cited Publications

    GSK-3 Cancer
    LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.
    LY2090314
  • HY-12012
    SB 216763
    40+ Cited Publications

    GSK-3 Autophagy Neurological Disease Cancer
    SB 216763 is potent, selective and ATP-competitive GSK-3 inhibitor with IC50s of 34.3 nM for both GSK-3α and GSK-3β.
    SB 216763
  • HY-113914
    9-ING-41
    5+ Cited Publications

    Elraglusib

    GSK-3 Apoptosis Autophagy Cancer
    9-ING-41 (Elraglusib) is a maleimide-based ATP-competitive and selective glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 0.71 μM. 9-ING-41 significantly leads to cell cycle arrest, autophagy and apoptosis in cancer cells. 9-ING-41 has anticancer activity and has the potential for enhancing the antitumor effects of chemotherapeutic agents [3] .
    9-ING-41
  • HY-10590
    TWS119
    30+ Cited Publications

    Wnt GSK-3 Autophagy Neurological Disease Cancer
    TWS119 is an inhibitor of GSK-3β, with an IC50 of 30 nM, and activates the wnt/β-catenin pathway.
    TWS119
  • HY-N8423
    α-Amyrin
    1 Publications Verification

    ERK GSK-3 Apoptosis Caspase COX Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    α-Amyrin is a pentacyclic triterpenoid compound with oral activity. α-Amyrin activates the ERK and GSK-3β signaling pathways. α-Amyrin can inhibit cancer cells proliferation and induce apoptosis. α-Amyrin shows anti-bacterial and anti-inflammation activity. α-Amyrin can reduce blood glucose level. α-Amyrin can be used for the researches of cancer, infection, inflammation, metabolic disease and neurological disease, such as breast cancer, Streptococcus oralis infection, skin inflammation and diabetes [3] .
    α-Amyrin
  • HY-12292
    IM-12
    5+ Cited Publications

    Wnt GSK-3 Cancer
    IM-12 is an inhibitor of GSK-3β, with an IC50 of 53 nM, and also enhances Wnt signalling.
    IM-12
  • HY-59090
    1-Azakenpaullone
    3 Publications Verification

    1-Akp

    GSK-3 Neurological Disease Metabolic Disease
    1-Azakenpaullone (1-Akp) is a highly selective and ATP-competitive inhibitor of glycogen synthase kinase-3 β (GSK-3β), with an IC50 value of 18 nM .
    1-Azakenpaullone
  • HY-130795
    GSK-3β inhibitor 2
    1 Publications Verification

    GSK-3 Neurological Disease
    GSK-3β inhibitor 2 (Compound 3) is a potent, selective and orally active GSK-3β inhibitor with an IC50 of 1.1 nM. GSK-3β inhibitor 2 can cross the blood-brain barrier. GSK-3β inhibitor 2 has the potential for Alzheimer's disease .
    GSK-3β inhibitor 2
  • HY-11012
    TDZD-8
    10+ Cited Publications

    GSK- Inhibitor I; NP 01139

    GSK-3 Cancer
    TDZD-8 is an inhibitor of GSK-3β, with an IC50 of 2 μM; TDZD-8 shows less potent activities against Cdk-1/cyclin B, CK-II, PKA, and PKC, with all IC50s of >100 μM.
    TDZD-8
  • HY-10512
    AR-A014418
    15+ Cited Publications

    AR 0133418; GSK inhibitor VIII; AR 014418

    GSK-3 Metabolic Disease Cancer
    AR-A014418 is a potent, selective and ATP-competitive GSK3β inhibitor (IC50=104 nM; Ki=38 nM) .
    AR-A014418
  • HY-15761
    AZD2858
    5+ Cited Publications

    GSK-3 Neurological Disease
    AZD2858 is a potent, orally active GSK-3 inhibitor, with IC50s of 0.9 and 5 nM for GSK-3α and GSK-3β, respectively, used in the research of fracture healing.
    AZD2858
  • HY-126144
    GSK-3β inhibitor 1
    4 Publications Verification

    GSK-3 Metabolic Disease Cancer
    GSK-3β inhibitor 1 (compound 3a) inhibits GSK-3β with an IC50 of 4.19 nM. GSK-3β inhibitor 1 demonstrates high antidiabetic efficacy in obese Streptozotocin (HY-13753)-treated rats .
    GSK-3β inhibitor 1
  • HY-100207
    CP21R7
    5+ Cited Publications

    CP21

    GSK-3 Cancer
    CP21R7 is potent GSK-3β inhibitor, with an IC50 of 1.8 nM; CP21R7 also shows inhibitory activitiy against PKCα, with an IC50 of 1900 nM.
    CP21R7
  • HY-145669
    DIF-3
    5+ Cited Publications

    Wnt CDK GSK-3 Infection Cancer
    DIF-3 is an orally active anticancer agent. DIF-3 reduces the expression levels of cyclin D1 and c-Myc by facilitating their degradation via activation of GSK-3β. DIF-3 inhibits Wnt/β-catenin signaling pathway-related proteins in cells. DIF-3 induces reactive oxygen species (ROS) and autophagy. DIF suppresses the growth of Trypanosoma. cruzi in HT1080 cells. DIF-3 exerts antitumor effects both in vitro and in vivo [3] .
    DIF-3
  • HY-149845

    PROTACs GSK-3 Neurological Disease
    PROTAC GSK-3β Degrader-1 (compound 1) is a degrader targets GSK-3β degradation with an IC50 value of 833 nM. PROTAC GSK-3β Degrader-1 contains SB-216763 (a GSK-3β inhibitor), a PEG linker and a CRBN (E3 ligase liand). PROTAC GSK-3β Degrader-1 reduces the neurotoxicity induced by Aβ25-35 peptide and CuSO4. PROTAC GSK-3β Degrader-1 can be used to research in Alzheimer's disease .
    PROTAC GSK-3β Degrader-1
  • HY-153166

    PROTACs GSK-3 Tau Protein Neurological Disease
    PT-65 is a GSK3α and GSK3β PROTAC degrader with DC50 values of 28.3 nM and 34.2 nM, respectively. PT-65 inhibits excessive tau phosphorylation mediated by GSK3β, Aβ and Okadaic acid (HY-N6785). PT-65 is applicable for the research of Alzheimer's disease .
    PT-65
  • HY-141480
    GSK-3β inhibitor 3
    1 Publications Verification

    GSK-3 Apoptosis Cancer
    GSK-3β inhibitor 3 is a potent, selective, irreversible and covalent inhibitor of Glycogen Synthase Kinase 3β (GSK-3β), with an IC50 of 6.6 μM. GSK-3β inhibitor 3 can be used for the research of acute promyelocytic leukemia .
    GSK-3β inhibitor 3
  • HY-124607B
    BRD3731
    2 Publications Verification

    GSK-3 Neurological Disease Metabolic Disease
    BRD3731 is a selective GSK3β inhibitor, with IC50s of 15 nM and 215 nM for GSK3β and GSK3α, respectively. BRD3731 is potentail for the research of post-traumatic stress disorder (PTSD), psychiatric disorder, diabetes, and neurodegenerative disorders .
    BRD3731
  • HY-P10605

    Akt GSK-3 Cancer
    GSK3β-peptide is a substrate mimetic peptide of glycogen synthase kinase 3(GSK3-β) that can bind to the active site of GSK3-β and mimic the behavior of a real substrate. GSK3β-peptide can be used to develop substrate mimetic inhibitors of Akt as potential anticancer drugs .
    GSK3β-peptide
  • HY-149054

    GSK-3 Tau Protein AAK1 Pim PKC Neurological Disease
    GSK-3β inhibitor 13 (compound 47) is an orally active and potent GSK-3β inhibitor with blood-brain permeability. GSK-3β inhibitor 13 inhibits GSK-3β and GSK-3α with IC50s of 0.73 nM and 0.35 nM, respectively. GSK-3β inhibitor 13 significantly decreases the phosphorylation of tau (IC50=58 nM), which leads the formation of the neurofibrillary tangles associated with Alzheimer's disease .
    GSK-3β inhibitor 13
  • HY-14679

    GSK-3 Neurological Disease
    GSK3β inhibitor II is an inhibitor of GSK3β. GSK3β inhibitor II can be used for research of Alzheimer’s disease (AD) .
    GSK3β inhibitor II
  • HY-164907

    GSK-3 Neurological Disease
    GSK-3β inhibitor 22 (compound 20o) is a GSK-3β inhibitor with an IC50 of 3.1 nM. GSK-3β inhibitor 22 has the potential of the study of Alzheimer's disease .
    GSK-3β inhibitor 22
  • HY-148561

    CDK GSK-3 PKC Cancer
    CDK8-IN-12 is an orally active, potent CDK8 inhibitor with a Ki of 14 nM. CDK8-IN-12 has off-target kinase inhibition on GSK-3α, GSK-3β, PCK-θ with Kis of 13 nM, 4 nM, 109 nM, respectively. CDK8-IN-12 shows potent anti-proliferative effects selectively on MV4-11 cell. CDK8-IN-12 is an anti-cancer agent .
    CDK8-IN-12
  • HY-122026

    PF-367

    GSK-3 Neurological Disease
    PF-04802367 (PF-367) is a highly selective GSK-3 inhibitor with an IC50 of 2.1 nM based on a recombinant human GSK-3β enzyme assay and 1.1 nM based on ADP-Glo assay. PF-04802367 shows desirable central nervous system (CNS) properties and potency. PF-04802367 is equally effective at inhibition of the two known GSK-3 isoforms (GSK-3α and GSK-3β) with IC50 values of 10.0 and 9.0 nM in mobility shift assays, respectively .
    PF-04802367
  • HY-120902

    Wnt GSK-3 Inflammation/Immunology
    GSK-3β inhibitor 8, a thiophenacil derivative, is an effective and selective inhibitor of GSK-3β (IC50=64 nM). GSK-3β inhibitor 8 negatively regulated Wnt signaling pathway and stimulated β cell proliferation .
    GSK-3β inhibitor 8
  • HY-144290

    GSK-3 DYRK Neurological Disease
    ARN25068 is a sub-micromolar inhibitor of the three protein kinases, GSK-3β, FYN and DYRK1A to tackle tau hyperphosphorylation .
    ARN25068
  • HY-P1173

    Myristoylated L 803; GSK- Inhibitor XIII

    GSK-3 Amyloid-β Neurological Disease
    L803-mts (Myristoylated L 803) is a selective and substrate-competitive GSK-3 peptide inhibitor (IC50: 40 μM). L803-mts also reduces Aβ deposits and ameliorates cognitive deficits in 5XFAD mice. L803-mts shows antidepressive effect in the forced swimming test .
    L803-mts
  • HY-137472

    GSK-3 Neurological Disease
    SAR502250 is a potent, selective, ATP competitive, orally active and brain-penetrant inhibitor of GSK3, with an IC50 of 12 nM for human GSK-3β. SAR502250 displays antidepressant-like activity. SAR502250 can be used for the research of Alzheimer’s disease (AD) .
    SAR502250
  • HY-N6580

    PI3K Akt GSK-3 Reactive Oxygen Species (ROS) TNF Receptor Interleukin Related Infection Metabolic Disease Inflammation/Immunology
    Ginsenoside Rg4 is an orally active protopanaxatriol type ginsenoside. Ginsenoside Rg4 can activate PI3K, AKT and GSK-3β signaling. Ginsenoside Rg4 can inhibit ROS and inflammatory cytokine levels. Ginsenoside Rg4 can be used for the researches of inflammation, infection and metabolic disease, such as sepsis and lung inflammation [3].
    Ginsenoside Rg4
  • HY-154852

    GSK-3 CDK Neurological Disease
    GSK-3 inhibitor 4 is an orally active and brain-penetrant inhibitor of GSK-3, CDK2, and CDK5, with IC50 values of 0.56 nM (GSK-3β), 0.45 nM (GSK-3α), 0.47 μM, and 0.68 μM, respectively. GSK-3 inhibitor 4 effectively reduces the phosphorylation level of Tau protein. GSK-3 inhibitor 4 can be used in Alzheimer's disease (AD) studies .
    GSK-3 inhibitor 4
  • HY-172171

    GSK-3 β-catenin Wnt Neurological Disease
    GSK3β-IN-2 (Compound S01) is the inhibitor for GSK3β with an IC50 of 0.35 nM. GSK3β-IN-2 activates Wnt/β-catenin signaling pathway, promotes neurogenesis and neurite growth. GSK3β-IN-2 inhibits Aβ-induced tau hyperphosphorylation at Ser396, reduces the formation of neurofibrillary tangles. GSK3β-IN-2 ameliorates Alzheimer's Disease in zebrafish model .
    GSK3β-IN-2
  • HY-10096

    GSK-3 Neurological Disease
    TCS2002 (Compound 9b) is a highly selective, orally bioavailable and potent GSK-3β inhibitor with the IC50 of 35 nM. TCS2002 shows good pharmacokinetic profiles including favorable BBB penetration. TCS2002 can be used for the research of Alzheimer’s disease .
    TCS2002
  • HY-147134

    GSK-3 Neurological Disease
    GSK-3β inhibitor 10 (compound 14a) is a highly potent GSK-3β inhibitor with an IC50 value of 80.5 nM. GSK-3β inhibitor 10 can be used for researching Alzheimer’s disease .
    GSK-3β inhibitor 10
  • HY-111055

    GSK-3 Neurological Disease
    BIP-135 is a potent and selective ATP-competitive GSK-3 inhibitor, with IC50s of 16 nM and 21 nM for GSK-3α and GSK-3β, respectively. BIP 135 exhibits neuroprotective effect .
    BIP-135
  • HY-149542

    Tau Protein Apoptosis GSK-3 Neurological Disease
    GSK-3β inhibitor 15 (Compound 54) is a GSK-3β inhibitor (IC50: 3.4 nM). GSK-3β inhibitor 15 inhibits Aβ1-42-induced GSK-3β and tau protein phosphorylation. GSK-3β inhibitor 15 inhibits LPS-induced iNOS expression. GSK-3β inhibitor 15 has neuroprotective effects on Aβ1-42-induced neurotoxicity. GSK-3β inhibitor 15 can be used for research of Alzheimer’s disease (AD) .
    GSK-3β inhibitor 15
  • HY-168857

    GSK-3 Tau Protein β-catenin Neurological Disease
    GSK-3β inhibitor 24 (Compound 41) is a potent GSK-3β inhibitor with an IC50 of 0.22 nM. GSK-3β inhibitor 24 increases GSK-3β phosphorylation at Ser9 site dose-dependently. GSK-3β inhibitor 24 inhibits the hyperphosphorylation of tau protein by decreasing the p-tau-Ser396 abundance. GSK-3β inhibitor 24 up-regulates β-catenin and neurogenesis-related markers (GAP43 and MAP-2). GSK-3β inhibitor 24 demonstrates remarkable anti-Alzheimer's disease (AD) effects .
    GSK-3β inhibitor 24
  • HY-179496

    GSK-3 Cholinesterase (ChE) Amyloid-β Neurological Disease
    ChE/GSK-3β-IN-1 (compound 18o) is a potent dual ChE/GSK-3β inhibitor. ChE/GSK-3β-IN-1 exhibits dual inhibition of AChE (IC50 = 1.7 μM), butyrylcholinesterase (BChE) (IC50 = 5.3 μM), and GSK-3β (IC50 = 5.7 μM). ChE/GSK-3β-IN-1 inhibits Aβ1-42 self-aggregation. ChE/GSK-3β-IN-1 can be used for Alzheimer’s disease (AD) research .
    ChE/GSK-3β-IN-1
  • HY-148132

    GSK-3 Neurological Disease
    GSK-3β inhibitor 11 (compound 21) is a glycogen synthase kinase-3β (GSK-3β) inhibitor (IC50=10.02 μM). GSK-3β inhibitor 11 can be used in neurodegenerative disease research .
    GSK-3β inhibitor 11
  • HY-170491

    GSK-3 Infection Neurological Disease
    GSK-3β inhibitor 23 (Compound 11726169) is the inhibitor for glycogen synthase kinase-3, that inhibits GSK-3β and GSK-3α with IC50 of 12.1 nM and 18.8 nM. GSK-3β inhibitor 23 exhibits antiviral activity against HIV 1. GSK-3β inhibitor 23 exhibits good metabolic stablility in mouse/human liver microsomes and plasma, but poor Caco-2 permeability (which predicts low oral bioavailability) .
    GSK-3β inhibitor 23
  • HY-126144A

    GSK-3 Metabolic Disease
    (E/Z)-GSK-3β inhibitor 1 is a racemic compound of (E)-GSK-3β inhibitor 1 and (Z)-GSK-3β inhibitor 1 isomers. GSK-3β inhibitor 1 (compound 3a) is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy, with an IC50 of 4.9 nM .
    (E/Z)-GSK-3β inhibitor 1
  • HY-162913

    GSK-3 Neurological Disease
    GSK-3β inhibitor 20 (compound 3A) is an potent inhibitor of GSK-3β with an IC50 value of 74.4 nM .
    GSK-3β inhibitor 20
  • HY-174272

    GSK-3 Amyloid-β Neurological Disease
    GSK-3β inhibitor 27 (Compound 1c) is a reversible and competitive GSK-3β inhibitor with an IC50 value of 2.2 μM. GSK-3β inhibitor 27 inhibits tau hyperphosphorylation, reduces Aβ protein aggregation and possesses metal chelation and neuroprotective potential. GSK-3β inhibitor 27 is promising for research of neurodegenerative diseases (such as Alzheimer’s disease) .
    GSK-3β inhibitor 27
  • HY-148133

    GSK-3 Neurological Disease
    GSK-3β inhibitor 12 (Compound 15) is a GSK-3β inhibitor. GSK-3β inhibitor 12 is applicable to the research of Alzheimer's disease .
    GSK-3β inhibitor 12
  • HY-175850

    GSK-3 Apoptosis NF-κB c-Myc Cancer
    GSK-3β inhibitor 28 is selective and non-competitivea glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 14.82 nM. GSK-3β inhibitor 28 can upregulate the expression level of phosphorylated GSK-3β and downregulate the expression of p-NF-κB, P65, C-myc and Cyclin D1. GSK-3β inhibitor 28 can induce cells apoptosis, G1 phase arrest and inhibit migration. GSK-3β inhibitor 28 can be used for the research of cancer, such as colorectal cancer .
    GSK-3β-IN-28
  • HY-144826

    GSK-3 Neurological Disease
    ZDWX-25 is a highly potent GSK-3β and DYRK1A dual inhibitor with an IC50 value of 71 nM for GSK-3β. ZDWX-25 possesses significant cytotoxic activities against SH-SY5Y and HL-7702 cells. ZDWX-25 can be used for researching alzheimer's disease .
    ZDWX-25
  • HY-172599

    GSK-3 Neurological Disease
    GSK-3β probe-1 (10c) is a GSK-3β probe (Ex = 341 nm, Em= 574nm, ɛ= 3.51 × 10 4L/mol·cm −1) and can be be used in the study of Alzheimer's disease .
    GSK-3β probe-1
  • HY-143261

    GSK-3 Metabolic Disease Inflammation/Immunology Cancer
    GSK-3β inhibitor 7 is a GSK-3β inhibitor with an IC50 value of 5.25 μM. GSK-3β inhibitor 7 is inserted into the ATP-binding binding pocket of GSK-3β and forms hydrogen-bond. GSK-3β inhibitor 7 shows high hepatocyte glucose uptake (83.5%), and can be used in the research of numerous diseases like diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder .
    GSK-3β inhibitor 7
  • HY-169024

    GSK-3 Neurological Disease Inflammation/Immunology
    GSK-3β inhibitor 19 (compound 36) is a GSK-3β inhibitor, with IC50 of 70 nM. GSK-3β inhibitor 19 can be used in anti-inflammatory and Alzheimer's disease related research .
    GSK-3β inhibitor 19
  • HY-176287

    Dopamine Receptor GSK-3 PKA P-glycoprotein Neurological Disease
    ARN25657 is a dual-acting D3R/GSK-3β modulator. ARN25657 has both partial D3R agonist activity (EC50 = 15.2 nM, Ki =1.5 nM) and potent GSK-3β inhibitor activity (IC50 = 19.3 nM). ARN25657 exhibits excellent GSK-3β selectivity over FYN, PKA, and CDK5/p35. ARN25657 inhibits P-glycoprotein (P-gP)-mediated acetoxymethyl calcein efflux and improves in vitro ADME properties while maintaining a balanced dual-target profile. ARN25657 is useful for studying bipolar disorder and related neuropsychiatric disorders .
    ARN25657

온라인 문의

Your information is safe with us. * Required Fields.

호칭

 

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

 

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: